18 results about "Hepatitis A" patented technology

The invention discloses an NDRV [sigma] C circular RNA vaccine and application thereof, and belongs to the technical field of vaccines.Duck hepatitis A virus type 1 (DHAV-1) UTR and T4 bacteriophage I type intron self-splicing cyclization systems are adopted to construct circular RNA (CirRNA-[sigma] C) for expressing NDRV [sigma] C protein, and a vaccine preparation is prepared through a chitosan-polyethyleneimine (CS-PEI) nano delivery system. The feasibility of a circular RNA vaccine system based on DHAV-1UTR in poultry vaccines is confirmed for the first time, the established nano delivery technology and circular RNA vaccine platform have the characteristics of high stability, good safety, strong immunogenicity and the like, and an important technical path is provided for development of novel vaccines of NDRV and other viral epidemic diseases.

The invention relates to the technical field of vaccine preparation, in particular to a freeze-drying method suitable for large-scale preparation of hepatitis A attenuated live vaccines. The invention relates to a freeze-drying method suitable for large-scale preparation of a hepatitis A attenuated live vaccine, which comprises the following steps: loading a semi-finished product of the hepatitis A attenuated live vaccine to be freeze-dried into a freeze-drying box, and then executing a freeze-drying procedure of two-stage drying. According to the invention, a multi-step freeze-drying path with multi-temperature gradient combination and multi-vacuum degree gradient is arranged on the large-scale freeze dryer to realize the microscopic change of the vaccine in the freeze-drying process, so that the efficient conversion from a laboratory to large-scale production is realized, the total freeze-drying time is less than 37 hours, the total time is shortened by about 50%, the production efficiency is favorably improved, and energy conservation and consumption reduction are facilitated.

A pharmaceutical composition including an active ingredient, wherein the active ingredient includes at least a first drug conjugate having a structure shown by the following formula: Z-(linker-[R]m)n. In the formula, Z is a drug compound, R is a sugar, and m and n are independently an integer from 1 to 6. The drug compound Z is a first drug compound X selected from the group consisting of Tenofovir, Tenofovir diisoproxil, Tenofovir alafenamide, Entecavir, Telbivudine, Adefovir, Adefovir dipivoxil, Lamivudine, Interferon-α-2A, Interferon-α-2B, Selgantolimod, BI-82 and Zosuquidar, and the sugar R is selected from the group consisting of a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, an oligosaccharide, and a polysaccharide.

Described herein are methods and compositions relating to inhibition of bile salt hydrolase (BSH) and uses thereof. Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (e.g., gastrointestinal infections; inflammatory bowel disease (IBD); appendicitis; crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; a liver disease (e.g., non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis), gastroesophageal reflux disease (GERD); celiac disease; diverticulosis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; intestinal leakage; the present invention relates to a method for treating a cancer (e.g., digestive cancer, liver cancer), a cancer (e.g., digestive cancer, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis). The method comprises administering to the subject a compound of Formula (I)-(XVIII).

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

The invention discloses a recombinant duck enteritis virus for expressing 3-type duck hepatitis A virus immunogenic genes and a construction method and application thereof. The recombinant duck enteritis virus is characterized in that an eukaryotic expression cassette containing a type 3 duck hepatitis A virus immunogenic gene is inserted into a non-coding region between UL26 and USL27 genes of a duck enteritis virus genome. According to the invention, a duck hepatitis A virus (DHAV) immunogenic gene is inserted into a duck enteritis virus (DEV) genome at a fixed point by virtue of a CRISPR / Cas9 gene editing technology, so that the recombinant duck enteritis virus for expressing the duck hepatitis A virus type 3 immunogenic gene is constructed and obtained. Moreover, based on the recombinant duck enteritis virus for expressing the 3-type duck hepatitis A virus immunogenicity gene constructed by the invention, the exogenous DHAV immunogenicity gene can be stably expressed in the recombinant virus, and the recombinant virus has good in-vitro replication ability and hereditary stability and can be used for preparing animal vaccines.

The present invention relates to a hepatitis A virus production method and hepatitis A virus produced according to the method, and, more specifically, to: a hepatitis A virus production method and hepatitis A virus produced according to the method, the method comprising the step of infecting a host cell with a virus obtained by transforming a host cell with a vector comprising an expression cassette, which comprises a hepatitis A virus gene, for hepatitis A virus preparation, and subculturing same.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The application discloses a duck hepatitis A virus type 3 VP0 polypeptide and a preparation method and application of a polyclonal antibody thereof, and belongs to the technical field of biochemistry and molecular immunology. The duck hepatitis A virus type 3 VP0 polypeptide has an amino acid sequence as shown in SEQ ID NO. 2. A polyclonal antibody is prepared by immunizing Kunming mice with the polypeptide. The polyclonal antibody of the duck hepatitis A virus type 3 VP0 polypeptide is obtained by immunizing an antiserum with a VP0 polypeptide coupled with KLH as an antigen. The polyclonal antibody preparation method is simple, low in cost, high in antibody titer, and capable of specifically recognizing the duck hepatitis A virus type 3 VP0 protein in eukaryotic cells.

The invention belongs to the technical field of biology, and particularly relates to a recombinant baculovirus capable of simultaneously expressing gene type 1 and gene type 3 duck hepatitis A virus VP1 protein and application of the recombinant baculovirus in preparation of a duck hepatitis A divalent subunit vaccine. The recombinant baculovirus co-expressing the gene type 1 and gene type 3 duck hepatitis A virus VP1 protein is constructed, the virus titer is high, and the two proteins can be expressed. Therefore, the recombinant baculovirus provided by the invention can be used for research and development and epidemic disease prevention and control of novel vaccines for duck viral hepatitis A.

The application belongs to the field of immunoassay and biosensing technology, and provides a preparation method of an ECL sensor based on near-infrared alkyne functionalized Cu NSs and a double-cycle waste-free Cas12a driven signal amplifier. Specifically, alkyne functionalized Cu NSs are used as luminophores, and the unique alkyne structure and rigid conformation of the ligand BPTA not only realize pi-pi ordered stacking, but also inhibit non-radiative transition and promote the formation of highly conjugated aggregates, so that the Cu NSs exhibit stable and efficient NIR-ECL performance at 803 nm wavelength, excellent biocompatibility and low cost advantage. In addition, based on the DNA recycling and reuse realized by the designed double-cycle strategy, and the excellent reaction kinetics and specificity of the Cas12a system, the double-cycle waste-free Cas12a driven signal amplifier not only solves the problem of DNA waste liquid in the traditional cycle, but also overcomes the defects of low cutting efficiency and poor specificity existing in the traditional enzyme cutting method. According to the difference in electrochemiluminescence signal intensity of different concentrations of the measured substance, the detection of hepatitis A virus HAV is realized.

The present invention relates to the field of viral molecular biology detection by establishing a dual real-time fluorescence quantitative PCR primer set and kit for duck hepatitis A virus type 1 and duck astrovirus type 3. This method can rapidly detect duck hepatitis A virus type 1 and duck astrovirus type 3. The method is simple and rapid, with a single sample detection time of 90 minutes and a sensitivity of up to 10 copies / μl. Simultaneous detection is possible for larger sample sizes, and the method exhibits excellent sensitivity, repeatability, specificity, and stability, enabling rapid and accurate detection of duck hepatitis A virus type 1 and duck astrovirus type 3.

The invention belongs to the field of food safety, and discloses a shellfish aquatic product hepatitis A virus nano PCR primer pair and a rapid detection kit. According to long-term experimental accumulation, a hepatitis A virus conserved sequence as shown in SEQ ID NO.3 is determined as a detection target, and the specific amplification efficiency is very good. By adding colloidal gold particles into a reaction system, the sensitivity of the kit for detecting the hepatitis A virus is further improved, the sensitivity is improved by 104 times compared with that of a common PCR detection method, and the kit has no cross reaction on common pathogenic microorganisms in shellfish aquatic products. The kit disclosed by the invention does not need expensive instruments and equipment, is high in specificity and sensitivity, and can be suitable for detecting a large batch of samples.

Provided is an anti-HAV antibody usable as a prophylactic agent and a therapeutic agent for hepatitis A.　The present invention pertains to: an anti-HAV antibody or an antigen-binding fragment thereof; a pharmaceutical composition and a reagent composition containing the antibody or the antigen-binding fragment thereof; a nucleic acid encoding the antibody or the antigen-binding fragment thereof; a vector including the nucleic acid; a host cell transformed by using the nucleic acid or the vector; and a method for producing the antibody or the antigen-binding fragment thereof.

The invention discloses a 1-type duck hepatitis A virus BJ80 strain, a vaccine and application of the 1-type duck hepatitis A virus BJ80 strain and the vaccine. The preservation number of the duck hepatitis A virus type 1 BJ80 strain is CCTCC (China Center For Type Culture Collection) NO: V202567. The 1-type duck hepatitis A virus attenuated strain with the preservation number of CCTCC NO: V202567 is obtained through chicken embryo passage and attenuation, and the technical problems that an existing DHAV-1 virulent strain is high in virulence and poor in safety, and an existing vaccine is strong in virulence, unstable in immune effect, short in storage life and the like are successfully solved; the low virulent strain is safe to ducklings, high in hereditary stability, free of strong reversion after continuous passage and good in immunogenicity, can induce generation of effective immune protection after inoculation, and provides a reliable core seed virus for preparation of safe and efficient bivalent live vaccines for duck virus hepatitis.

A drug conjugate includes a structure shown by the following formula: Z-(linker-[R]m)n. In the formula, Z is a drug compound, R is a sugar, and m and n are independently an integer from 1 to 6. The drug compound Z is a hepatitis virus targeting drug, a hepatitis B virus (HBV) drug, an inhibitor of apoptosis protein (IAP) antagonist, a multidrug resistance (MDR) inhibitor, or analogues, precursors, prodrugs, derivatives thereof.

This invention discloses the application of duck IL7 protein as an adjuvant in the preparation of duck hepatitis A virus type 3 inactivated vaccine, belonging to the field of biopharmaceuticals. The research of this invention shows that duck IL7 protein as an adjuvant can enhance the immunoprotective efficacy of the DHAV-3 inactivated vaccine and also enhance its heterologous protective ability. This provides a theoretical basis for the development of duck IL7 as a novel duck vaccine adjuvant.